An observational study in Rare Histiocytic Disorders (RHDs), Erdheim-Chester Disease (ECD) and Rosai-Dorfman Disease (RDD), sponsored by The Hospital for Sick Children. Recruiting at 15 sites in 9 countries. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by The Hospital for Sick Children · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Erdheim-Chester Disease with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Erdheim-Chester Disease · United States.
Among the 15 studies in Erdheim-Chester Disease with a site in United States, this one is one of 2 that started in 2014, is one of 8 observational ones, and was the 4th registered.
22 studies on the registry are indexed under Erdheim-Chester Disease; 11 are open to participants now.
Browse Erdheim-Chester Disease studies →7 of the 15 studies in Erdheim-Chester Disease with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Meyer Children's Hospital IRCCS · Sites in United States, France, Italy and 1 more country
Ages 7+
University of Alabama at Birmingham · Sites in United States
Ages 0–89
Carl Allen · Sites in United States
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Erdheim-Chester Disease studies recruiting now, 8 (73%) set no upper age limit and 1 (9%) stops at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4
First in 2011; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 37 across the 7 interventional studies, 325 across the 8 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 10 most frequent:
The Hospital for Sick Children is the lead sponsor of 579 studies on the registry; 81 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
The Hospital for Sick Children has 1 study filed under Erdheim-Chester Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Erdheim-Chester Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03990428Memorial Sloan Kettering Cancer CenterSupportive Care Needs of Caregivers of People With Erdheim-Chester Disease and Other Histiocytic Diseases | 2027-06 |
| NCT05915208University of Alabama at BirminghamHistiocytic Disorder Follow-up Study | 2027-07 |
| NCT05093335Memorial Sloan Kettering Cancer CenterIn-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | 2027-10 |
| NCT03329274Memorial Sloan Kettering Cancer CenterRegistry for Patients With Erdheim-Chester Disease and Other Histiocytoses | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Erdheim-Chester Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease that resolves spontaneously, to progressive disseminated forms that can be sometimes life-threatening. Since they are extremely rare, there is limited understanding of their causes and best treatment options. Physicians, patients and parents of children with RHDs frequently consult members of the Histiocyte Society regarding the best management of these disorders. Very often, no specific recommendation can be made due to the lack of prospective outcome data, or even large retrospective case series. The creation of an international rare histiocytic disorders registry (IRHDR) could facilitate a uniform diagnosis of the RHDs, as well as the collection and analysis of the clinical, epidemiological, treatment and survival data of patients with RHD. The registry may also lead to future therapeutic recommendations, provide a framework for future clinical trials and create excellent research opportunities.
Histiocytoses are rare diseases caused by an excess of cells called Histiocytes, which can infiltrate the skin, bones, lungs, liver, spleen and the central nervous system. These disorders can range from localized involvement that resolves spontaneously, to progressive disseminated forms that can be debilitating and sometimes life-threatening. The rare histiocytic disorders (RHD), or non-Langerhans cell disorders, are a diverse group of disorders defined by the accumulation of histiocytes that do not meet the criteria for Langerhans cell histiocytosis (LCH) or hemophagocytic lymphohistiocytosis (HLH). They include: Juvenile xanthogranuloma family, Erdheim-Chester disease, Multifocal Reticulohistiocytosis, Rosai-Dorfman disease and the Malignant Histiocytoses. Since they are so rare, there is limited understanding of their causes and treatments. Physicians, patients and parents of children with rare histiocytoses frequently consult members of the Histiocyte Society on the management of these disorders. Very often, no specific recommendation about treatment can be made due to the lack of prospective outcome data for these rare entities. The creation of an International Rare Histiocytic Disorders Registry (IRHDR) will facilitate a uniform diagnosis of the RHD's, as well as the collection and analysis of the clinical, epidemiological, treatment and survival data of patients with RHD. The registry will also provide expert pathology reviews and may lead to future therapeutic recommendations. Furthermore, the IRHDR can provide a framework for future clinical trials, thus, creating excellent research opportunities. Lastly, a de-identified link between clinical data and companion biology studies can potentially be accomplished in the future through the IRHDR. This may further help in understanding the etiology of these rare diseases, as well as identifying potential therapeutic targets.
Rare Histiocytic Disorders:
Xanthogranuloma Family (XG)
Rosai-Dorfman disease (RDD)
Malignant Histiocytic Neoplasm (MHN)
Mixed Histiocytosis (MXH)
Other
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No intervention.
Collecting data on disease presentation, treatments used and treatment outcomes over time for patients diagnosed with RHD to better understand the diseases and optimize the treatments.
Collecting data on disease presentation, treatments used and treatment outcomes over time for patients diagnosed with RHD to better understand the diseases and optimize the treatments. Data will be analysed on average yearly, the registry will be ongoing for 10 years.
Time frame: Data will be analysed on average yearly, the registry will be ongoing for 10 years.
Develop treatment guidelines for the RHD based on solid clinical trial data.
Develop treatment guidelines for the RHD based on solid clinical trial data. Data will be analysed on average yearly, the registry will be ongoing for 10 years.
Time frame: Data will be analysed on average yearly, the registry will be ongoing for 10 years.
Not enrolling at this site.
The record gives a start of Oct 2014, a primary completion of Sep 2028 and a completion of Sep 2028. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hospital for Sick Children →